Compare Live Nation Entertainment, Inc. (LYV) vs Medpace Holdings Inc (MEDP) Price & Performance

Live Nation (LYV) trades at $184.65, showing minimal daily movement (+0.01%) amid strong analyst support with 87% buy ratings. The stock maintains a bullish technical outlook with key resistance at $186 and support at $181. Recent Q2 2026 earnings beat expectations with $1.05 EPS versus $0.66 estimate, driven by record concert attendance and international demand growth. Revenue reached $25.2B in 2025, though net margins remain thin at 0.51%.

The outlook remains positive given robust demand for live events and raised 2026 guidance, but high valuation multiples (P/E 117.5) and legal/regulatory risks warrant caution. Insider selling activity and negative ROE (-116.7%) highlight execution challenges despite strong top-line performance. Upside to consensus $209.54 target depends on margin expansion and debt management.

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.